Abstract
Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Current Genomics
Title: RNA-Based Gene Therapy for Haemophilia B
Volume: 6 Issue: 6
Author(s): M. P. Peppelenbosch, F. Milano, C. V. Ferreira, A. Knapinska, S. H. Diks and C. A. Spek
Affiliation:
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Abstract: Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Export Options
About this article
Cite this article as:
Peppelenbosch P. M., Milano F., Ferreira V. C., Knapinska A., Diks H. S. and Spek A. C., RNA-Based Gene Therapy for Haemophilia B, Current Genomics 2005; 6 (6) . https://dx.doi.org/10.2174/138920205774483052
DOI https://dx.doi.org/10.2174/138920205774483052 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transfersomes: The Ultra-Deformable Carrier System for Non-Invasive Delivery of Drug
Current Drug Delivery Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Electrospun Fibers for Dental and Craniofacial Applications
Current Stem Cell Research & Therapy Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Computational Approaches for Fragment-Based and De Novo Design
Current Topics in Medicinal Chemistry Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Medicinal Chemistry Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology